Global Identification of Biofilm-Specific Proteolysis in Candida albicans.

https://escholarship.org/uc/item/970817wk

mBio, 7(5)

2150-7511

Winter, Michael B
Salcedo, Eugenia C
Lohse, Matthew B
et al.

2016-09-13

10.1128/mbio.01514-16

Peer reviewed
Global Identification of Biofilm-Specific Proteolysis in *Candida albicans*

Michael B. Winter,* Eugenia C. Salcedo,b Matthew B. Lohse,c,d Nairi Hartooni,e Megha Gulati,f Hiram Sanchez,g,h Julie Takagi,c Bernhard Hube,j David R. Andes,g,h Alexander D. Johnson,c Charles S. Craik,a Clarissa J. Nobilec,f,h

Department of Pharmaceutical Chemistry, University of California, San Francisco, California, USAa; Chemistry and Chemical Biology Graduate Program, University of California, San Francisco, California, USAa; Department of Microbiology and Immunology, University of California, San Francisco, California, USAa; Biosynthese, Inc., San Francisco, California, USAa; Tetrad Graduate Program, University of California, San Francisco, California, USAa; Department of Molecular and Cell Biology, University of California, Merced, California, USAa; Department of Medicine, University of Wisconsin, Madison, Wisconsin, USAa; Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USAa; Department of Microbial Pathogenicity Mechanisms, Hans Knoll Institute, Jena, Germanyi

E.C.S., M.B.L., and N.H. contributed equally to this work.

**ABSTRACT** *Candida albicans* is a fungal species that is part of the normal human microbiota and also an opportunistic pathogen capable of causing mucosal and systemic infections. *C. albicans* cells proliferate in a planktonic (suspension) state, but they also form biofilms, organized and tightly packed communities of cells attached to a solid surface. Biofilms colonize many niches of the human body and persist on implanted medical devices, where they are a major source of new *C. albicans* infections. Here, we used an unbiased and global substrate-profiling approach to discover proteolytic activities produced specifically by *C. albicans* biofilms, compared to planktonic cells, with the goal of identifying potential biofilm-specific diagnostic markers and targets for therapeutic intervention. This activity-based profiling approach, coupled with proteomics, identified Sap5 (*Candidapepsin-5*) and Sap6 (*Candidapepsin-6*) as major biofilm-specific proteases secreted by *C. albicans*. Fluorogenic peptide substrates with selectivity for Sap5 or Sap6 confirmed that their activities are highly upregulated in *C. albicans* biofilms; we also show that these activities are upregulated in other *Candida* clade pathogens. Deletion of the SAP5 and SAP6 genes in *C. albicans* compromised biofilm development *in vitro* in standard biofilm assays and *in vivo* in a rat central venous catheter biofilm model. This work establishes secreted proteolysis as a promising enzymatic marker and potential therapeutic target for *Candida* biofilm formation.

**IMPORTANCE** Biofilm formation by the opportunistic fungal pathogen *C. albicans* is a major cause of life-threatening infections. This work provides a global characterization of secreted proteolytic activity produced specifically by *C. albicans* biofilms. We identify activity from the proteases Sap5 and Sap6 as highly upregulated during *C. albicans* biofilm formation and develop Sap-cleavable fluorogenic substrates that enable the detection of biofilms from *C. albicans* and also from additional pathogenic *Candida* species. Furthermore, SAP5 and SAP6 deletions confirm that both proteases are required for proper biofilm development *in vitro* and *in vivo*. We propose that secreted proteolysis is a promising marker for the diagnosis and potential therapeutic targeting of *Candida* biofilm-associated infections.

---

*Candida albicans* is a normal resident of the human microbiota, asymptptomatically colonizing many areas of the body, including the gastrointestinal tract, genitourinary tract, oral cavity, and skin of healthy individuals. However, *C. albicans* is also the most prevalent fungal pathogen of humans. Alterations in host immunity, damaged barrier functions, stress, and resident microbiota can lead to fungal overgrowth and infections. These infections range from superficial mucosal and dermal infections, such as thrush, vaginal yeast infections, and diaper rash, to hematogenously disseminated candidiasis with mortality rates as high as 47% (1). *C. albicans* infections can be especially serious in immunocompromised individuals, such as patients undergoing chemotherapy, transplantation patients receiving immunosuppression therapy, and healthy individuals with implanted medical devices (2–4).

A major medical impact of *C. albicans* results from its ability to form resilient and drug-resistant surface-associated communities called biofilms (5–9). Biofilms can form on all implanted medical devices, including catheters, pacemakers, dentures, contact lenses, and prosthetic joints, which provide efficient substrates for biofilm growth. Biofilms can also colonize biotic surfaces, such as mucosal and epithelial cells, with life-threatening colonization and invasion of parenchymal organs occurring once cells disperse from the biofilm and enter the bloodstream, resulting in dissem-
inated infections (5–9). In individuals with implanted medical devices, the standard treatment for device-associated biofilm infections is removal of the implanted device. This can require surgical intervention and is typically implemented after an infection has already disseminated (5–9). Therefore, the early and rapid detection of Candida biofilm formation is critical to improving patient outcome.

Recent genome-wide transcriptional analysis of C. albicans has identified certain secreted aspartyl protease (SAP)-encoding genes as being significantly upregulated during biofilm formation (10), and therefore, we hypothesized that extracellular protease activities could serve as biofilm-specific markers. To broadly test this hypothesis, we used a global approach to systematically identify extracellular protease activities in an unbiased way. To this end, a highly diverse 228-member synthetic peptide library was exposed to soluble factors produced by C. albicans biofilms, and the sequences cleaved in the peptide library were identified by mass spectrometry (MS). This approach, coupled with independent proteomic analyses, identified Sap5 (Candidapepsin-5) and Sap6 (Candidapepsin-6) as major biofilm-specific protease activities produced by C. albicans. Fluorogenic substrates that could distinguish between Sap5 and Sap6 were developed on the basis of preferential cleavages in the peptide library. These substrates both confirmed that Sap5 and Sap6 activities are highly upregulated during C. albicans biofilm formation and could distinguish between the biofilm and planktonic states of C. albicans. We also showed that these substrates could be used to detect biofilms of other pathogenic species in the Candida clade. To test whether Sap5 and Sap6 are required for biofilm formation, we evaluated C. albicans SAP5 and SAP6 deletion strains and found that the deletions compromised biofilm formation in vitro on the bottom of polystyrene plates and in a microfluidic flow device, as well as in vivo, in a rat central venous catheter biofilm model. These results show that Sap5 and Sap6, which can be used as biofilm-specific markers, are also required for proper biofilm development.

**RESULTS**

**Global protease profiling of biofilm and planktonic C. albicans.** To identify global profiles of proteolytic activity associated with biofilm formation, conditioned medium from a wild-type C. albicans strain grown under biofilm and planktonic (suspension) conditions was assayed by a recently developed substrate-profiling approach termed Multiplex Substrate Profiling by Mass Spectrometry (MSP-MS) (11). Matched 24-h conditioned medium preparations were incubated with a physicochemically diverse library of 228 synthetic 14-mer peptide substrates (12), and time-dependent peptide cleavage products were identified through liquid chromatography-tandem MS (LC-MS/MS). Comparison of the complex cleavage profiles revealed that biofilm conditioned medium displayed an overall higher proteolytic activity against the peptide library, on the basis of the total number of unique peptide cleavage events observed throughout the assay time course (n = 308 for the biofilm condition and n = 185 for the planktonic condition at 240 min) (Fig. 1A; see Fig. S1 in the supplemental material). Motif analysis was subsequently performed to identify the global protease substrate specificities of the biofilm and planktonic conditions. iceLogo representations (13) that consider both cleaved and uncleaved positions in the peptide library were employed to visualize the fold enrichment and de-enrichment of amino acids flanking each cleavage site (cleavage occurs between the P1 and P1′ positions) (Fig. 1A; see Fig. S1). Both the biofilm and planktonic conditions shared an enrichment of bulky hydrophobic residues (e.g., norleucine) and arginine at the P1 position, hydrophobic residues at the P1′ position, and arginine at the P2′ position.

The biofilm and planktonic conditions also yielded distinct cleavages against the peptide library (n = 202 for the biofilm condition and n = 79 for the planktonic condition) (Fig. 1B). To quantify differences in global substrate specificity between these conditions, Z scores (13) were used to generate a difference map derived from residue preferences at each subsite (Fig. 1C). This analysis revealed significant physicochemical differences in substrate specificity. The biofilm condition displayed an increased preference for basic residues (lysine and arginine) at the P1 and P1′ positions, whereas the planktonic condition displayed an increased preference for aspartic acid at the P1′ position and certain hydrophobic residues at the P1 and P1′ positions (e.g., P1′-tyrosine). In addition, the biofilm condition displayed an overall increased preference for non-prime-side hydrophobic residues (P4-P1), with the strongest preference for isoleucine at the P2 position. Because of the higher proteolytic activity evident in the C. albicans biofilm conditioned medium, we also compared assay time points with similar numbers of cleavages (60 and 240 min for the biofilm and planktonic conditions, respectively) to confirm these specificity differences (see Fig. S2 in the supplemental material). Together, our substrate profiling results indicate that, in addition to exhibiting higher total activity against the peptide library, the biofilm condition is associated with a distinct protease substrate specificity profile.

**Proteomic identification of biofilm-specific proteases.** To identify specific proteases that have increased abundance during biofilm formation, we performed shotgun proteomic analysis on matched conditioned medium preparations from wild-type C. albicans grown under biofilm and planktonic conditions. Two members of the Sap family, Sap5 and Sap6, were found to have significantly higher levels under biofilm conditions (8.7-fold with P = 3.7 × 10−6 for Sap5 and 40.2-fold with P = 9.1 × 10−5 for Sap6) using label-free quantitation of precursor ion abundance, with Sap5 and Sap6 being among the most differentially upregulated proteins in the biofilm state (Fig. 2). Kex2, the only other protease identified by shotgun proteomics, was found to have modestly higher abundance in biofilm conditioned medium (2.8-fold; P = 5.4 × 10−3). Kex2 is a single-pass transmembrane protease with a luminal catalytic domain that in Saccharomyces cerevisiae has proprotease processing roles in the trans-Golgi network and the late endosome/prevaccular compartment (14). Although the release of Kex2 into conditioned medium from small amounts of nonspecific cell lysis cannot be ruled out, recent characterization of the composition of the C. albicans biofilm matrix identified several cytosolic metabolic proteins (15), suggesting that the extracellular localization of Kex2, possibly through extracellular vesicle release (16), may represent a relevant biofilm-specific feature.

**Biofilm-specific cleavages are attributable to Sap5 and Sap6.** To assign biofilm-specific cleavages in the peptide library to the candidate proteases, mature Sap5, Sap6, and a soluble Kex2 construct were recombinantly expressed in Pichia pastoris and profiled with the MSP-MS assay. Sap5 and Sap6 were found to have broad substrate specificities against the peptide library, yielding >140 cleavages each after 240 min (Fig. 3A). Kex2 was found to have comparatively high specificity, with cleavages occurring after
K/R-R (P2-P1) pairings (see Fig. S3 in the supplemental material), in agreement with its biological processing role and the specificity previously reported for recombinantly produced Kex2 proteases (17).

Assessment of the global substrate specificity profiles of recombinantly produced Sap5 and Sap6 revealed shared residue preferences. These shared preferences include lysine and bulky hydrophobic residues (phenylalanine, tyrosine, norleucine, and leucine) at the P1 position, hydrophobic residues at the P4 through P2 positions, and arginine at the P2′ position (Fig. 3A). The Sap5 and Sap6 preferences resemble the biofilm cleavage profile (Fig. 1), consistent with the upregulation of Sap5 and Sap6 under the biofilm condition. Even though mature Sap5 and Sap6 share a high degree of sequence conservation (80%) and certain residue preferences, they also produced several unique cleavages against the peptide library (30% and 29% at 240 min for Sap5 and Sap6, respectively). A difference map calculated from position-specific Z scores further demonstrated pronounced differences in Sap5 and Sap6 substrate specificity (see Fig. S4 in the supplemental material).

To assess the contributions of Sap5 and Sap6 specificity to the complex conditioned medium profiles, conditioned medium was pretreated with the aspartyl protease inhibitor pepstatin A prior to analysis with the MSP-MS assay. The pepstatin-sensitive cleavages under the biofilm condition demonstrated a substrate specificity motif that shared the dominant specificity features of the purified Saps and most closely resembled the Sap6 cleavage profile (Fig. 3B). Any biofilm or planktonic conditioned medium cleavages that displayed pepstatin sensitivity and matched those derived from the recombinantly produced Sap5 and Sap6 proteases were attributed to Sap5 and Sap6 activity (Fig. 3C and D). By this approach, a larger proportion of biofilm-specific (39%) than planktonic-condition-specific (3%) cleavages could be attributed to these proteases (assay time points were chosen to normalize for the higher proteolytic activity under the biofilm condition). This analysis illustrates the significant increase in Sap5 and Sap6 activity in C. albicans biofilms, with Sap6 accounting for a larger proportion of the biofilm-specific cleavages than Sap5.

To date, Sap family proteases are the only C. albicans secreted proteases that have been reported. However, our global analysis...
revealed cleavages not attributable to Sap5 or Sap6 from proteases that were not detectable by shotgun proteomic analysis. These unassigned biofilm-specific cleavages display an overall preference for arginine and phenylalanine at the P1 position (see Fig. S5 in the supplemental material). In contrast, the unassigned planktonic-condition-specific cleavages display a distinct preference for bulky hydrophobic residues at both the P1 and P1’ positions. Mapping of cleavage site positions along the uncapped 14-mer peptide substrates also indicated comparatively higher aminopeptidase-like activity under the planktonic condition, with the majority of unassigned cleavages occurring one to three positions from the peptide N termini (see Fig. S5).

Construction of Sap5 and Sap6 fluorogenic peptide substrates. To develop fluorogenic probes for detecting biofilm-specific protease activity, we identified peptide sequences with selectivity for Sap5 and/or Sap6. MSP-MS peptides displaying high Sap5 and Sap6 activity were repositioned into a smaller 25-mer sublibrary, and a time course was used to refine cleavage preferences for these individual peptide substrates (Fig. 4A). Of the 29 cleavages with the highest activity, 8 were found to favor Sap5, whereas 13 were found to favor Sap6 (see Fig. S6 in the supplemental material). For each protease, two 8-mer peptide sequences containing P4-P4’ residues from Sap5- or Sap6-favored cleavages were selected for incorporation into internally quenched fluorogenic peptides. The fluorogenic probes were synthesized bearing either a 5-carboxyfluorescein or 7-methoxycoumarin fluorophore with a corresponding quencher positioned at the opposing terminus such that peptide cleavage yields a fluorescence signal. Among the fluorogenic substrates evaluated, the sequences VFILWRTE and TFSYNRWP were found to afford the highest selectivity for Sap5 or Sap6, respectively (Fig. 4B; see Fig. S7 in the supplemental material).

Sap5 and Sap6 activities are upregulated under the biofilm condition. In agreement with the prior MSP-MS cleavage site analysis, application of the fluorogenic substrates to the biofilm or planktonic conditioned medium revealed a dramatic increase in substrate cleavage under the biofilm condition, with the Sap6 substrate showing the higher induction (Fig. 4C). Pepstatin pretreatment resulted in a significant reduction in substrate cleavage, confirming predominant aspartyl protease activity (Fig. 4C). To confirm probe selectivity for the target proteases, conditioned medium preparations from sap5Δ/Δ and sap6Δ/Δ single deletion mutant strains and a sap5/6ΔΔ/ΔΔ double deletion mutant strain were also assayed (Fig. 4D). Deletion of both Sap5 and Sap6 in the double mutant significantly reduced the cleavage of both fluorogenic substrates under the biofilm condition, confirming that Sap5 and Sap6 are the major contributing activities. To our initial surprise, the individual sap5Δ/Δ and sap6Δ/Δ mutant strains did not show reductions in activity as dramatic as the sap5/6ΔΔ/ΔΔ double mutant strain. In the case of the individual sap5Δ/Δ deletion strain, activity against the Sap6 substrate increased, suggesting that upregulation of Sap6 activity is partially compensating for loss of Sap5. We note that the remaining substrate cleavage in the sap5/6ΔΔ/ΔΔ double deletion mutant strain indicates proteolytic activity from additional proteases, possibly reflecting compensation for loss of both Sap5 and Sap6.

Sap5 and Sap6 substrates enable biofilm detection across the Candida clade. We assessed the ability of the Sap5- and Sap6-cleavable fluorogenic substrates to distinguish between the biofilm and planktonic states of diverse pathogenic species from across the Candida clade (Fig. 5A to E). A panel of Candida clade species were grown under the biofilm and planktonic conditions established for C. albicans, and conditioned medium preparations were assayed for proteolytic activity with the VFILWRTE and TFSYNRWP fluorogenic substrates (Fig. 5A and B). Notably, proteolytic activity against these substrates was higher under the biofilm condition than under the planktonic condition across all of the species tested, including in two species found outside the Candida clade. Pepstatin pretreatment of biofilm conditioned medium revealed substrate-specific differences in aspartyl protease activity. The substrate VFILWRTE exhibited a reduction in cleavage upon pepstatin treatment across all of the species tested, with C. albicans exhibiting the greatest pepstatin sensitivity (Fig. 5C). In contrast, the most pronounced aspartyl protease activity against the TFSYNRWP substrate was restricted to the Candida clade (Fig. 5D). Together, these results suggest that aspartyl protease activity is linked to conserved biofilm-associated functions and that subtle differences in proteolytic activity may distinguish
between even closely related fungal species. Given the expansion of the Sap family in the _Candida_ clade (18), it is possible that pepstatin-sensitive substrate cleavage within these _Candida_ clade species is attributable to proteolytic activity from Sap family proteases. Although activities from different proteases or protease classes may also be relevant for cleavage of the fluorogenic substrates and even for biofilm formation in these species, proteolytic upregulation clearly distinguishes between biofilm and planktonic growth in the _Candida_ clade and beyond.

**Deletion of SAP5 and SAP6 compromises _C. albicans_ biofilm formation _in vitro_ and _in vivo_.** We next evaluated the effects of SAP5, SAP6, and SAP5/6 deletions on _C. albicans_ biofilm formation _in vitro_ and _in vivo_. Biofilms were quantified with a standard biofilm assay using optical density at 600 nm (OD$_{600}$) after 24 h of growth in a multiwell plate format as described previously (19). This analysis identified a significant reduction in biofilm formation by the _sap5_Δ/Δ, _sap6_Δ/Δ, and _sap5_Δ/sap6_Δ/ΔΔ deletion strains compared to that by the wild-type reference strain, with the _sap6_Δ/Δ and _sap5_Δ/sap6_Δ/ΔΔ mutants having the most noticeable defects (Fig. 6A). Reintroduction of wild-type alleles of _SAP5_ and _SAP6_ into the _sap5_Δ/Δ and _sap6_Δ/Δ deletion mutant strains, respectively, restored normal biofilm levels, validating the functional roles of both _SAP5_ and _SAP6_ in biofilm formation _in vitro_. The wild-type and mutant strains all displayed comparable growth rates in planktonic cultures (see Fig. S8 in the supplemental material), indicating that the biofilm defects were not a result of inherent growth differences.

Because of the reduction in _C. albicans_ biofilm formation, we independently quantified cellular adhesion under early biofilm-forming conditions immediately following the initial (90-min) adherence period. This analysis revealed a highly pronounced reduction in the number of adhered cells of the _sap5_Δ/Δ, _sap6_Δ/Δ, and _sap5_Δ/sap6_Δ/ΔΔ deletion strains compared to that by the wild-type reference strain, with the _sap6_Δ/Δ and _sap5_Δ/sap6_Δ/ΔΔ mutants having the most noticeable defects (Fig. 6A). Reintroduction of wild-type alleles of _SAP5_ and _SAP6_ into the _sap5_Δ/Δ and _sap6_Δ/Δ deletion mutant strains, respectively, restored normal biofilm levels, validating the functional roles of both _SAP5_ and _SAP6_ in biofilm formation _in vitro_.

![Figure 3](mbio.asm.org/FIG3.png)

**FIG 3** Global protease substrate specificity profiling reveals that Sap5 and Sap6 activities are highly increased in _C. albicans_ under biofilm growth conditions. (A) iceLogo representations of recombinantly produced Sap5 and Sap6 following 240 min of incubation with the MSP-MS peptide library (P = 0.05 for residues colored by physicochemical property). Further comparison of Sap5 and Sap6 specificity is shown in Fig. S4 in the supplemental material. (B) iceLogo representation of cleavages from the _C. albicans_ biofilm conditioned medium MSP-MS assay that are sensitive to pretreatment with the aspartyl protease inhibitor pepstatin A (10 μM). (C) Assignment of pepstatin-sensitive cleavages in the biofilm and planktonic profiles through comparison to recombinantly produced Sap5 and Sap6. The biofilm (60 min) and planktonic (240 min) time points were chosen to normalize for the higher total proteolytic activity under the biofilm condition. IceLogo representations for unassigned cleavages are distinct from the Sap5 and Sap6 specificity profiles and are provided in Fig. S5 in the supplemental material. (D) Example peptide cleavages from the biofilm (green arrows) and planktonic (yellow arrows) MSP-MS assays are shown with pepstatin-sensitive cleavages indicated by an X and the time point of first appearance noted. Selected cleavages were omitted for clarity. All MSP-MS cleavages identified are provided in Data Set S1 in the supplemental material.
FIG 4 Sap5- and Sap6-cleavable fluorogenic peptide substrates distinguish between C. albicans under biofilm and planktonic growth conditions. (A) Fluorogenic substrates were developed on the basis of Sap5 and Sap6 cleavages from the MSP-MS peptide library. An example MS-based time course is provided showing Sap6-favored cleavage of KWLHPTFSYNRWP, one substrate within a 25-member peptide sublibrary. Complete hydrolysis of the parent substrate and cleavage at a single site allowed for the calculation of \( k_{\text{cat}}/K_{\text{m}} \) values of \( 4.4 \times 10^4 \) M\(^{-1}\) s\(^{-1}\) (Sap5) and 2.0 \( \times \) 10\(^5\) M\(^{-1}\) s\(^{-1}\) (Sap6). Cleavage time courses for the remaining peptides used in sequence selection are provided in Fig. S6 in the supplemental material. (B) Activity (relative fluorescence units [RFU] per second per microgram) of the internally quenched fluorogenic substrates VFILWRTE (blue bars) and TFSYNRWP (red bars) against recombinantly produced Sap5 and Sap6. (C) Both VFILWRTE and TFSYNRWP displayed significantly higher activity (***, \( P < 0.001 \)) in 24-h biofilm (BF) than in planktonic (PK) conditioned medium from wild-type C. albicans (SN425). Pretreatment with 10 \( \mu \)M pepstatin A inhibits Sap5 and Sap6 activity. Similar activity and inhibition results were obtained with the wild-type SN250 reference strain and are provided in Fig. S7 in the supplemental material. (D) Cleavage of VFILWRTE and TFSYNRWP in conditioned medium from the wild-type reference (SN250) and sap5Δ/Δ, sap6Δ/Δ, and sap5/6ΔΔ/ΔΔ deletion strains. Deletion of both Sap5 and Sap6 significantly reduces the cleavage of both substrates. At least partial compensation of Sap6 activity is observed in the sap5Δ/Δ deletion strain. Activity was normalized to the wild-type biofilm activity for each substrate, and significant differences in biofilm activity are indicated (***, \( P < 0.001 \); n.s., not significant). Equivalent amounts of protein from conditioned medium preparations were used for each condition. For all results, mean activity is reported with error bars indicating the SD of triplicate values.

and sap5/6ΔΔ/ΔΔ deletion mutant strains relative to those of the wild-type strain (Fig. 6B) that correlated with their biofilm defects. The sap5/6ΔΔ/ΔΔ deletion strain exhibited an 85% reduction compared to the wild-type reference, suggesting that Sap5 and SAP6 play essential roles in initiating proper biofilm formation in vitro by contributing to cellular adhesion during the first stage of biofilm formation.

To better mimic physiological growth conditions, time-dependent biofilm formation for the sap5Δ/Δ, sap6Δ/Δ, and sap5/6ΔΔ/ΔΔ mutant and wild-type reference strains was also visualized in a microfluidic assay under dynamic flow conditions equivalent to the average flow rate of fluid across a typical intravascular human catheter (Fig. 6C) (20–22). Time-lapse microscopy videos of biofilm development were recorded for 12 h post-adherence to the microfluidic chamber surface (see Movie S1 in the supplemental material). In agreement with the OD\(_{\text{595}}\) measurements, quantification of biofilm formation under dynamic flow conditions revealed a marked reduction in biofilm growth for the sap6Δ/Δ and sap5/6ΔΔ/ΔΔ mutant strains compared to the wild-type reference strain and a less pronounced defect for the sap5Δ/Δ strain (Fig. 6C). This assay suggests that SAP5 and SAP6 play roles in C. albicans biofilm formation over time, with SAP6 playing the larger role as the biofilm matures.

Finally, we evaluated the effect of SAP5/6 deletion on in vivo C. albicans biofilm formation with a rat central venous catheter biofilm model (23). Catheters surgically implanted in the jugular vein underwent intraluminal infection with the sap5/6ΔΔ/ΔΔ mutant strain or the wild-type reference strain. Following a 4-h adherence period, the catheters were flushed, and after 24 h, biofilm formation on the intraluminal catheter surface was assessed by scanning electron microscopy (SEM). The sap5/6ΔΔ/ΔΔ deletion strain exhibited a significant reduction in biofilm formation in vivo compared to the wild-type reference strain, as noted by a visibly evident decrease in C. albicans cells that had adhered to the catheter surface (Fig. 6D). The lack of significant biofilm formation in vivo in the rat catheter model and in the in vitro biofilm models suggests that Sap5 and Sap6 play key roles in the formation of device-associated biofilms and that this may occur, at least in part, by contributing to cellular adhesion during biofilm initiation.
To evaluate the effect of SAP5/6 deletion on C. albicans planktonic virulence in vivo, we also tested the sap5/6ΔΔ/ΔΔ mutant strain in a murine tail vein injection model of hematogenously disseminated candidiasis (which does not require biofilm formation). In agreement with a recent report (24), the sap5/6ΔΔ/ΔΔ deletion mutant strain did not show a reduction in C. albicans planktonic virulence compared to the wild-type reference strain in intravenously infected BALB/c mice on the basis of both survival time and kidney burden (see Fig. S8 in the supplemental material). This result is consistent with our observation that deletion of SAP5 and SAP6 does not compromise the growth of C. albicans in the planktonic state but that it has a profound effect on biofilm formation.

**DISCUSSION**

The ability of Candida species to form biofilms on biotic surfaces and implanted medical devices provides a major source of new infections and presents a special treatment challenge, as biofilms are resistant to conventional antifungal drugs (8). Early and rapid diagnosis of biofilm-associated infections is necessary to improve patient outcomes and requires the identification of biofilm-specific molecular markers. Beginning with a global activity-based approach, we identified Sap5 and Sap6 as major secreted biofilm-specific protease activities. Global substrate specificity profiling, coupled with the design of specific peptide substrates, showed that Sap5 and Sap6 activities greatly increase during C. albicans biofilm formation and that our fluorogenic probes could distinguish between the biofilm and planktonic states of C. albicans. We also showed that this is true for several additional pathogenic species in the Candida clade. Finally, the deletions of SAP5 and SAP6 in C. albicans demonstrated that these proteases are essential for proper biofilm formation both in vitro and in vivo.

Previous efforts to characterize the functions of Sap5 and Sap6 have focused on their potential invasive roles (25–28). Indeed, SAP5 and SAP6 have been shown to be hyphae-specific genes (29, 30), with SAP6 induction observed in hyphae-infiltrated tissue (27). However, the results described here suggest that Sap5 and Sap6 have functions during biofilm formation distinct from the hyphal invasion of host tissues. Defects in cellular adhesion in the SAP5 and SAP6 deletion strains demonstrate that these proteases are required for proper adhesion by C. albicans during the initiation of biofilm formation. Sap5- and Sap6-mediated adhesion of C. albicans cells to abiotic surfaces may help to both seed the formation of biofilms and maintain their attachment to catheters and other implanted medical devices. In addition, SAP5 and SAP6 expression is dynamic during biofilm development (19, 31), suggesting that they may play a variety of different roles throughout biofilm maturation. For example, Sap5 and Sap6 may contribute to nutrient breakdown and acquisition, cell-cell communication, or extracellular matrix production. Indeed, expression of SAP5 and SAP6 is considerably higher (≥50-fold) in vivo in mature biofilms isolated from the rat catheter model than in planktonic cells (31), further supporting the relevance of Sap5 and Sap6 in mature biofilm infections.

The strong induction of Sap5 and Sap6 proteolytic activities in biofilms and in vivo upregulation suggests that Sap5 and Sap6 may be promising biofilm diagnostic markers. Current clinical ap-
proaches for diagnosing Candida infections are hampered by low sensitivity, slow turnaround times, and a lack of species specificity (32, 33). These approaches also fail to distinguish between biofilm and planktonic cells. We envision that fluorogenic peptide substrates with biofilm (or planktonic) selectivity could be used as ex vivo diagnostic tools through noninvasive blood sampling. The catalytic signal amplification by proteolytic activity (34) makes these probes particularly sensitive. Development of rapid and noninvasive approaches for detecting Candida biofilm formation would change current clinical practices by enabling the early identification of biofilms, well before they have had a chance to seed life-threatening disseminated infections.

Although the main goal of our work is to ultimately discover rapid diagnostics for C. albicans biofilms, we also found that Sap5 and Sap6 are necessary for biofilm formation in vitro and in vivo, suggesting that they may be useful as biofilm-specific therapeutic targets for preventing or inhibiting biofilm growth. Saps produced by C. albicans during infections have been previously suggested as therapeutic targets. For example, HIV aspartyl protease inhibitors were observed to inhibit C. albicans growth in the clinic, possibly by inhibiting various Saps (35, 36). In all, C. albicans has 10 SAP genes, and they have previously been implicated in many aspects of pathogenesis, including invasion, cell wall protein shedding, hyphal cell aggregation, nutrient acquisition, activation of the host inflammatory response, and immune escape (25, 37–40). Although the precise mechanistic roles of Sap5 and Sap6 in biofilm formation are not yet known, the substrate specificity preferences identified here may ultimately lead to the discovery of their endogenous substrates.
MATERIALS AND METHODS

Reagents. The reagents used in this study were obtained from the following commercial sources. BD Bacto peptone, BD Bacto yeast extract, BD Diﬀco yeast nitrogen base without amino acids, and BD Diﬀco nutrient broth were from Becton, Dickinson, and Company. RPMI 1640 medium with l-glutamine and 4-morpholinoepanesulfonic acid (MOPS) and without sodium bicarbonate was from Lonza. Phosphate-buffered saline (PBS), Dulbecco’s PBS (D-PBS), ampicillin, and gentamicin were from the University of California, San Francisco (UCSF) cell culture facility. Glucose and acetonitrile were from Fisher. Biotin, methanol, mono- and dibasic potassium phosphate, citric acid, sodium chloride, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol (Bis-Tris), diithiothreitol (DTT), iodacetamide, ammonium bicarbonate, pepstatin A, EDTA, 2-(N-morpholino)ethanesulfonic acid (MES), N,N-di- methylformamide (DMF), N-methylmorpholine, 4-methylpiperidine, triisopropylsilane, Trition X-100, and mannitol were from Sigma-Aldrich. Glycerol was from Acros Organics. Urea, formic acid, and potassium chloride were from J. T. Baker. Trifluoroacetic acid was from Thermo Scientiﬁc. Peptide synthesis reagents were from AnaSpec, Inc., or Nova-bioc hem (EMD Millipore) unless otherwise noted.

Strains. The wild-type C. albicans SN425 and SN250 strains (SC5314 background) have been described previously (41). Construction of the sap5Δ/Δ (SAP5MS4B) and sap6Δ/Δ (SAP6MS4B) single and sap5/6Δ/Δ (SAP5MS64B) double mutant strains has also been described previously (42). SAP5 and SAP6 complementation strains CJN2833 and CJN2833, in the sap5/6Δ/Δ (SAP5MS64B) mutant backgrounds, respectively, were constructed by cloning SAP5 and SAP6 exons (containing the 800-bp sequence upstream of the start codon and the 500-bp sequence downstream of the stop codon) into plasmid pCP055 (43); integration into C. albicans was veriﬁed by colony PCR. For C. dublinensis (CD36), C. tropicalis (ATCC MYA-3404), Spastahpora passalidurans (ATCC MYA-4345/NRLR Y-27907), and C. glabrata (CBS138), a sequenced strain was used; isolates other than the sequenced strain were used for mutagenesis (17). P. pastoris cultures (1 liter) were grown to saturation in buffered glycerol complex medium for 2 days at 30°C. Cells were harvested and resuspended in 200 ml of buffered methanol complex medium containing 0.5% methanol. Protein expression was carried out for 2 days for Sap5 and Sap6 and for 1 day for Kex2. Culture supernatant was passed through a 0.22-μm vacuum ﬁlter and stored at −80°C.

Recombinant protein expression. Recombinant Sap5, Sap6, and Kex2 were produced with a P. pastoris expression system using strains that have been described previously (45, 46). Kex2 from S. cerevisiae was selected for the present study because it has been produced successfully in P. pastoris, unlike C. albicans Kex2, and has similar substrate speciﬁcity (17). P. pastoris cultures (1 liter) were grown to saturation in buffered glycerol complex medium for 2 days at 30°C. Cells were harvested and resuspended in 200 ml of buffered methanol complex medium containing 0.5% methanol. Protein expression was carried out for 2 days for Sap5 and Sap6 and for 1 day for Kex2. Culture supernatant was passed through a 0.22-μm vacuum ﬁlter and stored at −80°C.

Recombinant protein puriﬁcation. Recombinant C. albicans Sap5 and Sap6 were puriﬁed by an adaptation of the methods of Borelli et al. (47). Briefly, culture supernatant was concentrated to 15 ml with a spin ﬁlter with a 10-kDa cutoff and dialyzed against 4 liters of 10 mM sodium citrate buffer (pH 7.0) for 4 h, followed by a second overnight dialysis. Dialyzed supernatant was concentrated to 5 ml with a spin ﬁlter with a 10-kDa cutoff and loaded at 0.5 ml/min onto a 5-ml HiTrap SP HP column (GE Healthcare) that had been equilibrated with 10 mM sodium citrate (pH 7.0). Protein was resolved at 4 ml/min with a gradient of 10 mM sodium citrate (pH 7.0) containing 300 mM NaCl while 5-ml fractions were collected. Fractions containing the highest-purity Sap5 or Sap6 as assessed by SDS-PAGE were pooled and concentrated to 1 ml with a spin ﬁlter with a 10-kDa cutoff. Pooled protein was loaded at 0.25 ml/min onto a Superdex 200 10/300-GL column (GE Healthcare) that had been equilibrated with 10 mM sodium citrate (pH 7.0) containing 150 mM NaCl. Protein was resolved with an isocratic ﬂow of 1 ml/min while 1-ml fractions were collected. Fractions containing puriﬁed Sap5 or Sap6, as assessed by SDS-PAGE, were pooled and concentrated to 1 ml.

For recombinant S. cerevisiae Kex2, culture supernatant was prepared as described above for Sap5 and Sap6. However, dialysis was performed with 50 mM Bis-Tris (pH 5.0). Concentrated supernatant was loaded at 0.5 ml/min onto a 5-ml HiTrap Q HP column (GE Healthcare) that had been equilibrated with 50 mM Bis-Tris (pH 5.0). Protein was resolved at 4 ml/min with a gradient of 50 mM Bis-Tris (pH 5.0) containing 1 M NaCl while 5-ml fractions were collected. Fractions were concentrated using a Vivaspin Concentrator 10/30 kDa (Sartorius). Fractions containing the highest-purity Sap5 or Sap6 were pooled and concentrated to 1 ml.

Proteomic analysis of C. albicans bioﬁlm and planktonic condition medium. Triplcicate 24-h conditioned medium preparations (4 μg) from matched wild-type C. albicans (SN425) cultures grown under bioﬁlm and planktonic conditions were incubated with 6 M urea and 10 mM DTT for 20 min at 55°C. Samples underwent alkylation with 12.5 mM iodoacetyl-mide in the dark at ambient temperature for 1 h. Samples were quenched with 10 mM DTT, and the ﬁnal volume was diluted 3-fold into 25 mM ammonium bicarbonate. Trypsin digestion was performed with a 1:20 ratio of sequencing-grade trypsin (Promega) to total protein overnight at 37°C. Samples were acidified to approximately pH 2 with formic acid. Peptides were desalted with C18 Desalting Tips (Rainin), lyophilized, and rehydrated in 0.2% formic acid.

Peptide sequencing by LC-MS/MS was performed on an LTQ-Orbitrap XL mass spectrometer (Thermo) equipped with a nanoACQUITY (Waters) ultraperformance LC (UPLC) system and an EASY-
Spray ion source (Thermo). Reversed-phase chromatography was carried out with an EASY-Spray PepMap C18 column (Thermo, ES800; 3-μm bead size, 75 μm by 150 mm). The LC was operated at a 600-nl/min flow rate during sample loading for 20 min, the flow rate was reduced to 300 nl/min, and then peptides were separated over 30 min with a linear gradient of 2 to 50% (vol/vol) acetonitrile in 0.1% formic acid. For MS/MS analysis, survey scans were recorded over a mass range of 325 to 1,500 m/z. Peptide fragmentation was performed by collision-induced dissociation (CID) on the six most intense precursor ions, with a minimum of 1,000 counts, with an isolation width of 2.0 m/z and a minimum normalized collision energy of 25. Internal recalculation to polydimethylcyclosiloxane ions (m/z = 445.120025) was used for both MS and MS/MS scans.

MS peak lists were generated with in-house software called PAVA. Database searching was performed with Protein Prospector software, v.5.16.1 (http://prospector.ucsf.edu/prospector/mshome.htm, UCSE) (48) against the UniProtKB C. albicans (SC5314, taxonomic identifier 237561) database (downloaded 17 June 2013; 9,111 entries). The database was concatenated with an equal number of fully randomized entries for estimation of the false-discovery rate (FDR). Database searching was carried out with tolerances of 20 ppm for parent ions and 0.8 Da for fragment ions. Peptide sequences were matched as tryptic peptides with up to two missed cleavages. Constant and variable modifications were set as described previously (11). The following Protein Prospector score thresholds were selected for protein and peptide matches, respectively. Peptides with a minimum of two unique peptides for identification are reported. MS1 extracted ion chromatograms for label-free quantitation were obtained from Skyline software (v.3.5; University of Washington) (49). Statistical significance (P values) was calculated with a two-tailed t test. Supporting search and quantitation results are provided (see Data Set S1 in the supplemental material) for all of the proteins identified in matched biofilm and planktonic conditioned media from the wild-type (SN425) strain.

Multiplex substrate profiling by MS (MS-MS). Substrate specificity profiles were determined for 24-h conditioned medium from wild-type C. albicans (SN425) biofilm and planktonic cultures and for recombinant Sap5, Sap6, and Kex2 with the MS-MS assay (11). Conditioned medium preparations were profiled in the absence of inhibitor and following 30 min of preincubation on ice with 10 μM pepstatin A or 1 mM EDTA. Recombinant Saps and Kex2 were profiled in an identical manner in the absence of inhibitor and following pretreatment with either 10 μM pepstatin A (Saps) or 1 mM EDTA (Kex2). MS-MS assays were carried out as described previously (11). Briefly, 20 μg/ml conditioned medium, 2 μg/ml Sap5, 0.2 μg/ml Sap6, 2 μg/ml Kex2, and matched no-enzyme controls were assayed against a diversity of 228 tetrapeptides pooled at 500 nM in D-PBS (pH 7.4) for Kex2 or matched MES at pH 5.5 (9.5 mM MES, 2.7 mM KCl, 140 mM NaCl) for recombinant Saps and conditioned medium. Sap5 and Sap6 concentrations were selected to normalize for cleavage number. After 15, 60, and 240 min, 30 μl of assay mixture was removed, quenched with 7.5 μl of 20% formic acid, and flash-frozen in liquid N2. For sublibrary profiling with the recombinant Saps, 0.2 μg/ml Sap5 and Sap6 were assayed in the MES buffer (pH 5.5) against a sublibrary of 25 tetrapeptides pooled at 500 nM. After 1, 5, 15, 30, 120, 240, and 1,440 min, 29 μl of the assay mixture was removed and quenched with a mixture of 7.5 μl of 20% formic acid and 1 μl of 375 μM pepstatin A prior to being flash frozen in liquid N2. All peptide samples were desalted with C18 Desalting Tips, lyophilized, and rehydrated in 0.2% formic acid.

Cleavage site identification was performed with the LTQ Orbitrap-XL mass spectrometer, ion source and UPLC system described above. LC was done at a 600-nl/min flow rate during sample loading for 14 min and then at a 300-nl/min flow rate for peptide separation over 65 min with a linear gradient of 2 to 50% (vol/vol) acetonitrile in 0.1% formic acid. Peptide fragmentation was performed with the CID parameters described above. MS peak lists were generated with MScout, and data were searched against the 228-member peptide library with Protein Prospector and tolerances of 20 ppm for parent ions and 0.8 Da for fragment ions. All cleavages were allowed in the search by designating no enzyme specificity. The following variable modifications were used: amino acid (proline, tryptophan, and tyrosine) oxidation and N-terminal pyroglutamate conversion from glutamine. Protein Prospector score thresholds were selected with a minimum protein score of 22 and a minimum peptide score of 15. For the peptide sublibrary, a minimum protein score of 15 and a minimum peptide score of 10 were used. Maximum expectation values of 0.01 and 0.05 were selected for protein and peptide matches, respectively. Peptides corresponding to cleavage products in the 228-member library (12) were imported into iceLogo software v.1.2 (13) to generate substrate specificity profiles as described previously (11). Octapeptides corresponding to P4-P4′ were used as the positive data set, and octapeptides corresponding to all possible cleavages in the library (n = 2,964) were used as the negative data set. Octapeptide cleavage products identified by the MSP-MS assays with the 228-member library are provided in Data Set S1 in the supplemental material. Kinetic calculations for the peptide sublibrary were performed as described previously (11) except by employing precursor ion intensities for progress curve calculations. Data fitting was performed with Prism (v.6.0).

Peptide synthesis of fluorogenic substrates. The internally quenched fluorogenic substrate VFILWRTE, bearing a 5-carboxyfluorescein (5-FAM) fluorophore and a paired CPO2 quencher as CPO2–Val–Phe–Ile–Leu–Trp–Arg–Thr–Glu–Lys (5-FAM)–d-Arg–d-Arg–NH2, was custom synthesized by CPC, Scientific, Inc. The remaining substrates (IYRH-VQV, WPSnNKVG, and TFSyNRWP) were synthesized in house with a 7-methoxycoumarin (MCA) fluorophore and a 2,4-dinitrophenyl (DNP) quencher against standard 9-fluorenylethoxycarbonyl (Fmoc) peptide synthesis chemistry. The full peptide sequences are d-Arg–d-Arg–Lys(MCA)–Ile–Tyr–Arg–Nle–His–Val–Gin–Leu–DNS (DNP), d-Arg–d-Arg–Lys(MCA)–Trp–Pro–Ser–Nle–Asn–Lys–Val–Gly–Lys(DNP), and d-Arg–d-Arg–Lys(MCA)–Thr–Phe–Ser–Tyr–Nle–Arg–Trp–Pro–Lys(DNP). The first eight Fmoc-protected amino acids of each peptide were coupled to 150 mg of preloaded Fmoc-Lys(DNP) Wang resin (Anaspec, Inc.) with a Symphony Quartet 4-channel peptide synthesizer (Protein Technologies, Inc.). Double couplings for all steps were performed in DMF with Fmoc-amino acid (6.5 eq), N-methylmorpholine (13 eq), and 2-(1H-benzo-triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (6.5 eq), with the following exception. The Fmoc-Lys(MCA)-OH (Anaspec, Inc.) fluophore (3 eq) underwent a single overnight coupling with N-methylmorpholine (6 eq) and HBTU (3 eq). Fmoc deprotection for each step was afforded with 20% (vol/vol) 4-methylpyridine in DMF. Trifluoroacetic acid (TFA) cleavage was carried out with a solution of TFA (95%, vol/vol), water (2.5%, vol/vol), and triisopropylsilane (2.5%, vol/vol). Peptides were precipitated in diethyl ether, and the crude material was dried under ambient conditions. Peptides were purified on a preparative Vydc C18 column (22 by 250 mm, 10 μm) by reversed-phase high-performance LC (HPLC) with a gradient of 95% acetonitrile in 0.1% aqueous TFA. Matrix-assisted laser desorption ionization (MALDI) mass spectra were recorded on an Applied Biosystems Voyager DE-STR MALDI time-of-flight apparatus in positive-ion mode with a 1:1 (vol/vol) α-cyano-4-hydroxycinnamic acid-to-sample ratio. MS calculated (found): (M + H) IYRH-VQV, 1,991.0 (1,993.0); (M + H) WPSnNKVG, 1,849.9 (1,851.6); TFSyNRWP (M + H), 2,019.0 (2,020.6).

Protease activity assays. Activity assays were performed for up to 1 h in black 96-well round-bottom plates (Costar) with a BioTek Synergy H4 hybrid multimode microplate reader set to 37°C. The excitation and emission wavelengths used were, respectively, 328 and 393 nm (gain, 96) for MCA and 485 and 538 nm (gain, 94) for 5-FAM. Activity assays with conditioned medium were performed with 10 μM substrate and 10 or 20 μg/ml protein sample for VFLIRWTE and 10 μg/ml protein sample for TFSyNRWP. For assays with recombinant Saps, 2 μg/ml Sap5 and Sap6
were used with the following substrate concentrations: V1FILWRT6, 10 μM; 1YRnHVQL, 25 μM; WPSnNKVG, 25 μM; TFSynRW, 10 μM. Preincubation with 10 μM peptatin A was performed for 30 min on ice. All activity assays were performed in the MES (pH 5.5) buffer described above, which contained 0.01% Triton X-100 for recombinant enzyme activity measurements. Initial rates from a linear fit of the progress curves obtained with Gen5 Software v.2.03 are reported.

In vitro biofilm formation phenotype assays. Biofilm formation assays using OD₅₆₀ measurements were carried out as described previously (19). For adhesion assays, cells were allowed to adhere for 90 min in 96-well non-tissue–culture-treated polystyrene plates (Falcon) under biofilm-forming conditions. Nonadhering cells were subsequently removed, and the wells were washed twice with 200 μl of PBS. Adhering cells were vigorously resuspended in sterile water, serial dilutions were made, dilutions were plated onto YPD plates for 2 days at 30°C, and cells were quantified on the basis of CFU counting. Statistical significance was determined by one-way analysis of variance (ANOVA) (n = 12 for each biological sample). Time-dependent biofilm formation assays were performed under flow with a BioFlow EZ1000 (Fluxion Biosciences) micro-fluidic instrument. Briefly, overnight cultures grown at 30°C in YPD medium were diluted to a final OD₅₆₀ of 0.5 in Spider medium. Cells for each strain were seeded in three replicates on a BioFlow 48-Well Low-Shear plate (Fluxion Biosciences) and allowed to adhere at 37°C for 20 min. Nonadhering cells were washed away with flowing medium at 1 dyne/cm² for 5 min. The biofilms were grown for 12 h at 37°C with medium passage at 0.5 dyne/cm², and time-lapse images were captured every 5 min with a Zeiss AX10 microscope with a 20× objective for bright-field and phase-contrast microscopy for each well. Three fields of vision were used for each replicate, and representative images from select time points are shown. The mature biofilm was quantified with the BioFilm Montage software (Fluxion Biosciences), and the data are reported as percentages of the area occupied by the mature wild-type (SN250) biofilm, which was assigned a value of 100%. For representative videos of each strain, see Movie S1 in the supplemental material.

In vitro planktonic growth assays. Growth assays were performed by previously described methods (50). Briefly, cells from an overnight culture grown in YPD medium at 30°C were inoculated into 100 μl of YPD medium at a starting OD₅₆₀ of 0.01. The assay was performed with six replicates of each strain in flat-bottom 96-well plates (BD Falcon). Growth curves were generated in a BioTek plate reader at 30°C with orbital shaking at 400 rpm. OD₅₆₀ measurements were taken every 15 min for 24 h.

Animal models of C. albicans infection. All of the vertebrate animal experiments performed in this study were approved by the Institutional Animal Care and Use Committee at the appropriate institution that participated in the research. The rat central venous catheter biofilm model was used as previously reported (19, 23). Briefly, pathogen-free male rats (Sprague-Dawley) were implanted with a heparinized (100 μM polylethylene catheter (0.76-mm inside diameter, 1.52-mm outside diameter), which was inserted into the external jugular vein and advanced to a site above the atrium. Catheters were inserted 24 h prior to infection to permit deposition of host protein. Infection was achieved through intraluminal instillation with 500 μl of the sap5ΔΔ/ΔΔ double deletion mutant or SN250 wild-type reference strain (10⁶ cells/ml) with two rats per strain. The catheter volume was withdrawn and flushed with heparinized 0.15 M NaCl after a 4-h dwelling period, and catheters were removed after 24 h to assess biofilm growth on the intraluminal surface by SEM.

For the mouse model of hematogenously disseminated candidiasis (24), 12 female BALB/c mice (Simonsen Laboratories) weighing between 18 and 20 g were infected with the sap5ΔΔ/ΔΔ double deletion mutant or SN250 wild-type reference strain. Saturated C. albicans cultures were grown overnight in YPD medium at 30°C for 12 h. Cells were washed twice with sterile saline, and either 5.3 × 10⁶ cells (wild-type SN250) or 5.4 × 10⁵ cells (sap5ΔΔ/ΔΔ deletion mutant) in a 0.1-ml volume were delivered via tail vein injection. Mice were monitored daily and sacrificed when moribund. Three mice were injected with saline solution as a non-infected control. For kidney burden measurements, kidneys were dissected and flash frozen at the time of sacrifice. Kidneys were washed, placed in 1 ml of saline solution, and homogenized. Homogenates were plated onto synthetic complete medium containing ampicillin (50 μg/ml) and gentamicin (15 μg/ml) for CFU counting.

Statistics. Statistical significance (P values) was calculated with a two-tailed t test, except where noted otherwise. For protease activity assays with fluorogenic substrates, mean activity is reported with error bars indicating the standard deviations (SD) of triplicate values. For in vitro phenotype, adherence, and growth assays, n = 3 to 12 for each strain and the mean ± SD is reported (except when representative images are shown). For the mouse systemic infection model, n = 6 for each strain, which has been shown to be sufficient for providing statistical power (24). The rat catheter model was performed in biological duplicate. This animal model provides a test of clinical relevance and is not a quantitative assessment of biofilm formation. Mice for the systemic infection model were randomized for survival and kidney burden measurements. Investigators were not blinded to the group allocation or when assessing the outcomes of the systemic infection and catheter models.

Deposited data. All raw spectrum (.RAW) files from the proteomic and MSP-MS experiments in this study are available at the ProteoSAFe resource (ftp://MSV000079564@massive.ucsd.edu/; username MSV000079564, password Candida).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl?url=https://doi.org/10.1128/mbio.01514-16/-/DCSupplemental.

Movie S1, MOV file, 13.8 MB.
Data Set S1, XLSX file, 0.2 MB.
Figure S1, TIF file, 5.5 MB.
Figure S2, TIF file, 4.5 MB.
Figure S3, TIF file, 2.5 MB.
Figure S4, TIF file, 1.9 MB.
Figure S5, TIF file, 8.1 MB.
Figure S6, TIF file, 11.5 MB.
Figure S7, TIF file, 4.9 MB.
Figure S8, TIF file, 6.9 MB.

ACKNOWLEDGMENTS

MS was performed in collaboration with the UCSF Mass Spectrometry Facility (directed by Alma Burlingame). P. pastoris strains expressing C. albicans Sap5 and Sap6 and S. cerevisiae Kex2 were kind gifts from Michel Monod and Gyu Boileau. The sap5ΔΔ/ΔΔ and sap6ΔΔ/ΔΔ double deletion mutant strains were kind gifts from Joachim Morschhäuser. We thank Anatoly Urisman, Marcus Bohal, Natalia Khuri, Jeremy Horst, Glenda Polack, Ananda Mendoza, Andy Li-Wang, Anthony O’Donoghue, and Giselle Knudsen.

Clarissa Nobile and Alexander Johnson are cofounders of BioSynex, Inc., a company developing inhibitors and diagnostics of C. albicans biofilm formation, and Matt Lohse is an employee of Bio-Synex, Inc.

This study was supported by National Institutes of Health (NIH) grants R00AI100896 (to C.J.N.), R01AI083311 (to A.D.J.), R01GM104659 (to C.S.C.), R01AI073289 (to D.R.A.), and P41GM103481 (UCSF Mass Spectrometry Facility). M.B.W. was supported by NIH postdoctoral fellowship F32CA168130, and E.C.S. was supported by NIH training grant R25GM056847. This study was also supported by a UCSF Program for Breakthrough Biomedical Research (PBBR) award (to C.S.C. and M.B.W.) and two UCSF Enabling Technologies Advisory Committee (ETAC) awards (to C.S.C. and M.B.W.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

September/October 2016 Volume 7 Issue 5 e01514-16
FUNDING INFORMATION
This work, including the efforts of Michael B. Winter and Charles S. Craik, was funded by the UCSF Program for Breakthrough Biomedical Research (PBBR) Award. This work, including the efforts of Michael B. Winter and Charles S. Craik, was funded by the UCSF Enabling Technologies Advisory Committee (ETAC) Award. This work, including the efforts of Michael B. Winter, Eugenia C. Salcedo, Matthew B. Lohse, Nairi Hartooni, Megha Gulati, Hiram Sanchez, Julie Takagi, David Andes, Alexander D. Johnson, Charles S. Craik, and Clarissa J. Nobile, was funded by HHS | National Institutes of Health (NIH) (R01AI100896, R01AI083311, R01GM104639, P41GM103481, F32CA168130, R25GM056847, and R01AI073289).

REFERENCES
1. Pappas PG, Kaufman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr., Filler SG, Fisher JF, Kullberg JB, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535. http://dx.doi.org/10.1086/596757.
2. Calderone RA, Fonzi WA. 2001. Virulence factors of Candida albicans. Trends Microbiol 9:327–335. http://dx.doi.org/10.1016/S0966-842X(01)02094-7.
3. Kullberg BJ, Oude Lashof AM. 2002. Epidemiology of opportunistic invasive mycoses. Eur J Med Res 7:183–191.
4. Weig M, Gross U, Muhlschlegel F. 1998. Clinical aspects and pathogenesis of Candida infection. Trends Microbiol 6:468–470. http://dx.doi.org/10.1016/S0966-842X(98)01407-3.
5. Donlan RM. 2001. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 33:1387–1392. http://dx.doi.org/10.1086/322972.
6. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167–193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
7. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin Microbiol Rev 17:255–267. http://dx.doi.org/10.1128/CMR.17.2.255-267.2004.
8. Nobile CJ, Johnson AD. 2015. Candida albicans biofilms and human disease. Annu Rev Microbiol 69:71–92. http://dx.doi.org/10.1146/annurev-micro-091014-104330.
9. Gulati M, Nobile CJ. 2016. Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect 18:310–321. http://dx.doi.org/10.1016/j.micinf.2016.01.002.
10. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, O’Donoghue AJ, Knudsen GM, Ingram J, Zhou M, Johnson AD. 2015. An expanded regulatory network temporally controls Candida albicans biofilm formation. Mol Microbiol 96:1226–1239. http://dx.doi.org/10.1111/mmi.13002.
11. Li SF, Cole M, Forest R, Chilstrom M, Reinersman E, Jones MP, Zinzuwadia S, King S, Yadav K. 2010. Are 2 smaller intravascular catheters as good as 1 large intravascular catheter? Am J Emerg Med 28:724–727. http://dx.doi.org/10.1016/j.ajem.2009.05.003.
12. Wilson WC, Grande CM, Hoyt DB (ed). 2007. Trauma: emergency resuscitation, perioperative anesthesia, surgical management. CRC Press, Boca Raton, FL.
13. Bruchmann J, Sachsenhauser K, Rapp BE, Schwartz T. 2015. Multi-channel microfluidic biosensor platform applied for online monitoring and screening of biofilm formation and activity. PLoS One 10:e0117300. http://dx.doi.org/10.1371/journal.pone.0117300.
14. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 72:6023–6031. http://dx.doi.org/10.1128/IAI.72.10.6023-6031.2004.
15. Correia A, Lermann U, Teixeira I, Cerca F, Botelho S, da Costa RM, Sampaio P, Gatterter F, Morschhäuser J, Vilanova M, Pais C. 2010. Limited role of secreted aspartyl proteinases Sap1 to Sap6 in Candida albicans virulence and host immune response in murine hematothymogenously disseminated candidiasis. Infect Immun 78:4839–4849. http://dx.doi.org/10.1128/IAI.00248-10.
16. Naglik JR, Challacombe SJ, Hube B. 2003. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67:400–428. http://dx.doi.org/10.1128/MMBR.67.3.400-428.2003.
17. Wu H, Downs D, Ghosh K, Ghosh AK, Staib P, Monod M, Tang J. 2013. Candida albicans secreted aspartic proteinases 4–6 induce apoptosis of epithelial cells by a novel Trojan horse mechanism. FASEB J 27:2132–2144. http://dx.doi.org/10.1096/fj.12-214353.
18. Staib P, Kretschmar M, Nichterlein T, Hof H, Morschhäuser J. 2000. Differential activation of a Candida albicans virulence gene family during infection. Proc Natl Acad Sci U S A 97:6102–6107. http://dx.doi.org/10.1073/pnas.97.6102.
19. Hellmann A, Kretschmar M, Albrecht A, Schaller M, Beinhauer S, Nichterlein T, Sanglard D, Korting HC, Schäfer W, Hube B. 2002. Candida albicans hyphal formation and the expression of the Efg1-regulated proteases Sap4 to Sap6 are required for the invasion of parenchymal organs. Infect Immun 70:3689–3700. http://dx.doi.org/10.1128/IAI.70.7.3689-3700.2002.
20. White TC, Agabian N. 1995. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 177:5215–5221.
21. Hube B, Monod M, Schofield DA, Brown AJ, Gow NA. 1994. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 14:87–99. http://dx.doi.org/10.1111/j.1365-2958.1994.tb0169x.
22. Nakli H, Kuchariakova S, Ricicová M, Van Dijk P, Deforce D, Nelis H, Coenye T. 2010. Real-time PCR expression profiling of genes encoding potential virulence factors in Candida albicans biofilms: identification of model-dependent and independent gene expression. BMC Microbiol 10:114. http://dx.doi.org/10.1186/1471-2180-10-114.
23. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikian-Akdagli S, Bille J, Donnelly JP, Jensen HE, Lass-Flor C, Richardsen MD, Akova M, Bassetti M, Calandra T, Castagnola E, Corney OA, Garbino J, Gross AH, Herbrecht R, Hope WW, Kullberg JB, Lortholary O, Maeserens W, Petrikos K, Roilides E, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 18(Suppl 7):9–18. http://dx.doi.org/10.1111/1469-0691.12038.
33. Eggimann P, Bille J, Marchetti O. 2011. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 1:37. http://dx.doi.org/10.1186/2110-5820-1-37.

34. Page MJ, Lourenco AL, David T, LeBeau AM, Cattaruzza F, Castro HC, VanBrocklin HF, Coughlin SR, Craik CS. 2015. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nat Commun 6:8448.

35. Munro CA, Hube B. 2002. Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol 10:173–177. http://dx.doi.org/10.1016/S0966-842X(02)02331-2.

36. Cassone A, Cauda R. 2002. HIV protease inhibitors: do they really work against Candida in a clinical setting? Trends Microbiol 10:177–178. http://dx.doi.org/10.1016/S0966-842X(02)02341-7.

37. Pericolini E, Gabrielli E, Amacker M, Kasper I, Roselletti E, Luciano E, Sabbatini S, Kaeser M, Moser C, Hube B, Vecchiarelli A, Cassone A. 2015. Secretory aspartyl proteinases cause vaginitis and can mediate vaginitis caused by Candida albicans in mice. mBio 6:e00724. http://dx.doi.org/10.1128/mBio.00724-15.

38. Puris S, Kumar R, Chadha S, Tati S, Conti HR, Hube B, Cullen PJ, Edgerton M. 2012. Secreted aspartic protease cleavage of Candida albicans Mab2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis. PLoS One 7:e46020. http://dx.doi.org/10.1371/journal.pone.0046020.

39. Schild I, Heyken A, de Groot PW, Hiller E, Mock M, de Koster C, Horn U, Rupp S, Hube B. 2011. Proteolytic cleavage of covalently linked cell wall proteins by Candida albicans Sap9 and Sap10. Eukaryot Cell 10:98–109. http://dx.doi.org/10.1128/EC.00210-10.

40. Kumar R, Saraswat D, Tati S, Edgerton M. 2015. Novel aggregation properties of Candida albicans secreted aspartate proteinase Sap6 mediate virulence in oral candidiasis. Infect Immun 83:2614–2626. http://dx.doi.org/10.1128/IAI.00282-15.

41. Noble SM, French S, Kohn LA, Chen V, Johnson AD. 2010. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat Genet 42:590–598. http://dx.doi.org/10.1038/ng.605.

42. Lermann U, Morschhäuser J. 2008. Secreted aspartic proteases are not required for invasion of reconstituted human epithelia by Candida albicans. Microbiology 154:3281–3295. http://dx.doi.org/10.1099/mic.0.2008/022525-0.

43. Pérez JC, Kumanoto CA, Johnson AD. 2013. Candida albicans com-mensalism and pathogenicity are intertwined traits directed by a tightly knit transcriptional regulatory circuit. PLoS Biol 11:e1001510. http://dx.doi.org/10.1371/journal.pbio.1001510.

44. Mortimer RK, Johnston JR. 1986. Genealogy of principal strains of the yeast genetic stock center. Genetics 113:35–43.

45. Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M. 1998. The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 28:543–554. http://dx.doi.org/10.1046/j.1365-2958.1998.00815.x.

46. Lesage G, Tremblay M, Guimond J, Boileau G. 2001. Mechanism of Kex2p inhibition by its proreger. FEBS Lett 508:332–336. http://dx.doi.org/10.1016/S0014-5793(01)03096-4.

47. Borelli C, Ruge E, Lee JH, Schaller M, Vogelsang A, Monod M, Korting HC, Huber R, Maskos K. 2008. X-ray structures of Sap1 and Sap5: structural comparison of the secreted aspartic proteinases from Candida albicans. Proteins 72:1308–1319. http://dx.doi.org/10.1002/prot.22021.

48. Chalkley RJ, Baker PR, Medzhradszy KF, Lynn AJ, Burlingame AL. 2008. In-depth analysis of tandem mass spectrometry data from disparate instrument types. Mol Cell Proteomics 7:2386–2398. http://dx.doi.org/10.1074/mcp.M800021-MCP200.

49. Schilling B, Rardin MJ, MacLean BX, Zawadzka AM, Frewen BE, Cusack MP, Sorensen DJ, Bereman MS, Jing E, Wu CC, Verdin E, Kahn CR, Maccoss MJ, Gibson BW. 2012. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics 11:202–214. http://dx.doi.org/10.1074/mcp.M112.017707.

50. Wells ML, Washington OL, Hicks SN, Nobile CJ, Hartooni N, Wilson GM, Zucconi BE, Huang W, Li L, Fargo DC, Blackshear PJ. 2015. Post-transcriptional regulation of transcript abundance by a conserved member of the tristetraprolin family in Candida albicans. Mol Microbiol 95:1036–1053. http://dx.doi.org/10.1111/mmi.12913.

51. Lohse MB, Hernday AD, Fordyce PM, Noiman L, Sorrells TR, Hanson- Smith V, Nobile CJ, DeRisi JL, Johnson AD. 2013. Identification and characterization of a previously undescribed family of sequence-specific DNA-binding domains. Proc Natl Acad Sci U S A 110:7660–7665. http://dx.doi.org/10.1073/pnas.1221734110.

52. Sorrells TR, Booth LN, Tuch BB, Johnson AD. 2015. Intersecting transcrip-tion networks constrain gene regulatory evolution. Nature 523:361–365. http://dx.doi.org/10.1038/nature14613.